526 related articles for article (PubMed ID: 2036661)
1. Lymphocyte activation and serine-esterase induction following recombinant interleukin-2 infusion for lymphomas and acute leukaemias.
Lim SH; Worman C; Jewell A; Tsakona C; Giles FJ; Goldstone A
Cancer Immunol Immunother; 1991; 33(2):133-7. PubMed ID: 2036661
[TBL] [Abstract][Full Text] [Related]
2. Treatment of low-grade non-Hodgkin's lymphoma with continuous infusion of low-dose recombinant interleukin-2 in combination with the B-cell-specific monoclonal antibody CLB-CD19.
Vlasveld LT; Hekman A; Vyth-Dreese FA; Melief CJ; Sein JJ; Voordouw AC; Dellemijn TA; Rankin EM
Cancer Immunol Immunother; 1995 Jan; 40(1):37-47. PubMed ID: 7530170
[TBL] [Abstract][Full Text] [Related]
3. Immunologic and clinical modifications following low-dose subcutaneous administration of rIL-2 in non-Hodgkin's lymphoma patients after autologous bone marrow transplantation.
Lauria F; Raspadori D; Ventura MA; Rondelli D; Zinzani PL; Gherlinzoni F; Miggiano MC; Fiacchini M; Rosti G; Rizzi S; Tura S
Bone Marrow Transplant; 1996 Jul; 18(1):79-85. PubMed ID: 8831999
[TBL] [Abstract][Full Text] [Related]
4. Lymphocyte activation in patients with acute myeloid leukaemia. Evidence for the presence of myeloblast antigen?
Lim SH; Worman CP; Goldstone AH
Cancer Immunol Immunother; 1991; 33(6):417-20. PubMed ID: 1878895
[TBL] [Abstract][Full Text] [Related]
5. Biological monitoring of low-dose interleukin 2 in humans: soluble interleukin 2 receptors, cytokines, and cell surface phenotypes.
Hänninen EL; Körfer A; Hadam M; Schneekloth C; Dallmann I; Menzel T; Kirchner H; Poliwoda H; Atzpodien J
Cancer Res; 1991 Dec; 51(23 Pt 1):6312-6. PubMed ID: 1933892
[TBL] [Abstract][Full Text] [Related]
6. Activation of lymphocytes induced by recombinant human granulocyte-macrophage colony-stimulating factor in patients with malignant lymphoma.
Ho AD; Haas R; Wulf G; Knauf W; Ehrhardt R; Heilig B; Körbling M; Schulz G; Hunstein W
Blood; 1990 Jan; 75(1):203-12. PubMed ID: 2104762
[TBL] [Abstract][Full Text] [Related]
7. Continuous intravenous infusion of high-dose recombinant interleukin-2 for acute myeloid leukaemia--a phase II study.
Lim SH; Newland AC; Kelsey S; Bell A; Offerman E; Rist C; Gozzard D; Bareford D; Smith MP; Goldstone AH
Cancer Immunol Immunother; 1992; 34(5):337-42. PubMed ID: 1540980
[TBL] [Abstract][Full Text] [Related]
8. Independent expression of p55 and p75 interleukin-2 receptors (IL-2R) during intravenous or subcutaneous administration of recombinant interleukin-2 (rIL-2) by T-lymphocytes and natural killer cells.
Zambello R; Trentin L; Cerutti A; Enthammer C; Milani A; Franceschi T; Messina C; Cetto GL; Agostini C; Semenzato G
Cancer; 1994 Nov; 74(9):2562-9. PubMed ID: 7522954
[TBL] [Abstract][Full Text] [Related]
9. Recombinant interleukin-2 treatment before and after autologous stem cell transplantation in hematologic malignancies: clinical and immunologic effects.
De Laurenzi A; Iudicone P; Zoli V; De Rosa L; Guglielmetti M; Pescarollo A; Papetti C; Pacilli L; Lapponi P; Petti N
J Hematother; 1995 Apr; 4(2):113-20. PubMed ID: 7633841
[TBL] [Abstract][Full Text] [Related]
10. Generation and characterization of lymphokine-activated killer cells from non-Hodgkin's lymphoma patients.
Jhaver KG; Advani SH; Nadkarni JJ
Immunol Lett; 1990 Jun; 24(3):217-23. PubMed ID: 2384264
[TBL] [Abstract][Full Text] [Related]
11. Infusions of interleukin-1 alpha after autologous transplantation for Hodgkin's disease and non-Hodgkin's lymphoma induce effector cells with antilymphoma cytolytic activity.
Katsanis E; Weisdorf DJ; Xu Z; Dancisak BB; Halet ML; Blazar BR
J Clin Immunol; 1994 May; 14(3):205-11. PubMed ID: 7929695
[TBL] [Abstract][Full Text] [Related]
12. Production of tumour-derived suppressor factor in patients with acute myeloid leukaemia.
Lim SH; Worman CP; Jewell A; Goldstone AH
Leuk Res; 1991; 15(4):263-8. PubMed ID: 2030608
[TBL] [Abstract][Full Text] [Related]
13. Immunogenicity of recombinant human interleukin-2: biological features and clinical relevance.
Hänninen EL; Knüver-Hopf J; Atzpodien J
Biotherapy; 1993; 6(4):251-61. PubMed ID: 7517168
[TBL] [Abstract][Full Text] [Related]
14. Correlation between enhancement of graft-versus-leukemia effects following allogeneic bone marrow transplantation by rIL-2 and increased frequency of cytotoxic T-lymphocyte precursors in murine myeloid leukemia.
Leshem B; Vourka-Karussis U; Slavin S
Cytokines Cell Mol Ther; 2000 Sep; 6(3):141-7. PubMed ID: 11140883
[TBL] [Abstract][Full Text] [Related]
15. Clinical and immunologic effects of prolonged infusion of low-dose recombinant interleukin-2 after autologous and T-cell-depleted allogeneic bone marrow transplantation.
Soiffer RJ; Murray C; Cochran K; Cameron C; Wang E; Schow PW; Daley JF; Ritz J
Blood; 1992 Jan; 79(2):517-26. PubMed ID: 1730094
[TBL] [Abstract][Full Text] [Related]
16. Preclinical studies for adoptive immunotherapy in bone marrow transplantation. Generation of anti-CD3 activated cytotoxic T cells from normal donors and autologous bone marrow transplant candidates.
Ueda M; Joshi ID; Dan M; Uberti JP; Chou TH; Sensenbrenner LL; Lum LG
Transplantation; 1993 Aug; 56(2):351-6. PubMed ID: 8356589
[TBL] [Abstract][Full Text] [Related]
17. Eosinophils activation in post-autologous bone marrow transplanted patients treated with subcutaneous interleukin-2 and interferon-alpha 2A immunotherapy.
Fabian I; Kravtsov V; Elis A; Gurevitch O; Ackerstein A; Slavin S; Nagler A
Leukemia; 1994 Aug; 8(8):1379-84. PubMed ID: 8057677
[TBL] [Abstract][Full Text] [Related]
18. Detection of soluble IL-2 receptor in the serum and bone marrow of patients with minimal residual hematological malignancies: induction under therapy with IL-2.
Kandefer-Szerszeń M; Legieć W; Dmoszyńska A; Rzeski W
Arch Immunol Ther Exp (Warsz); 1997; 45(5-6):443-8. PubMed ID: 9437500
[TBL] [Abstract][Full Text] [Related]
19. Low doses of rIL2 after autologous bone marrow transplantation induce a "prolonged" immunostimulation of NK compartment in high-grade non-Hodgkin's lymphomas.
Raspadori D; Lauria F; Ventura MA; Tazzari PL; Ferrini S; Miggiano MC; Rondelli D; Tura S
Ann Hematol; 1995 Oct; 71(4):175-9. PubMed ID: 7578523
[TBL] [Abstract][Full Text] [Related]
20. Selective modulation of human natural killer cells in vivo after prolonged infusion of low dose recombinant interleukin 2.
Caligiuri MA; Murray C; Robertson MJ; Wang E; Cochran K; Cameron C; Schow P; Ross ME; Klumpp TR; Soiffer RJ
J Clin Invest; 1993 Jan; 91(1):123-32. PubMed ID: 7678599
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
